You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB01378
TypeSmall Molecule

Magnesium hydroxide is used primarily in “Milk of Magnesia”, a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.

SynonymsNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS number7439-95-4
WeightAverage: 24.305
Monoisotopic: 23.985041898
Chemical FormulaMg
magnesium(2+) ion
Mass SpecNot Available
KingdomInorganic Compounds
SuperclassHomogeneous Metal Compounds
ClassHomogeneous Alkaline Earth Metal Compounds
SubclassNot Available
Direct parentHomogeneous Alkaline Earth Metal Compounds
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionThis compound belongs to the homogeneous alkaline earth metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkaline earth metal atom.
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.8382
Blood Brain Barrier + 0.9708
Caco-2 permeable + 0.7056
P-glycoprotein substrate Non-substrate 0.8831
P-glycoprotein inhibitor I Non-inhibitor 0.9869
P-glycoprotein inhibitor II Non-inhibitor 0.9855
Renal organic cation transporter Non-inhibitor 0.9176
CYP450 2C9 substrate Non-substrate 0.8465
CYP450 2D6 substrate Non-substrate 0.823
CYP450 3A4 substrate Non-substrate 0.8094
CYP450 1A2 substrate Non-inhibitor 0.8824
CYP450 2C9 substrate Non-inhibitor 0.9221
CYP450 2D6 substrate Non-inhibitor 0.9555
CYP450 2C19 substrate Non-inhibitor 0.9469
CYP450 3A4 substrate Non-inhibitor 0.9846
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9015
Ames test Non AMES toxic 0.9663
Carcinogenicity Carcinogens 0.6381
Biodegradation Ready biodegradable 0.9031
Rat acute toxicity 2.0881 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9462
hERG inhibition (predictor II) Non-inhibitor 0.9716
ManufacturersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Experimental Properties
melting point651 °CPhysProp
boiling point1100 °CPhysProp
Predicted Properties
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
SpectraNot Available
Synthesis Reference

David S. Thompson, John S. Prestley, Jr., Thomas E. Webb, “Aluminum-magnesium alloys sheet exhibiting improved properties for forming and method aspects of producing such sheet.” U.S. Patent US4151013, issued 0000.

General ReferenceNot Available
External Links
KEGG CompoundC00305
PubChem Compound888
PubChem Substance46508750
Therapeutic Targets DatabaseDCL000876
ATC CodesA12CC08B05XA11A06AD03B05XA10A06AD19A02AA04A12CC09A02AA01A06AD02A12CC01A12CC04B05CB03A12CC07G04BX01A12CC03A02AA03A02AA02A12CC05A02AA05A06AD01A12CC06A12CC30
AHFS Codes
  • 28:08.04.24
  • 28:12.92
  • 40:12.00
  • 40:34.00*
  • 56:04.00
  • 56:12.00
  • 84:24.00
  • 84:92.00
  • 88:29.00*
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(73.4 KB)
Drug Interactions
AlendronateFormation of non-absorbable complexes
AmprenavirThe antiacid decreases the absorption of amprenavir
AtazanavirThis gastric pH modifier decreases the levels/effects of atazanavir
ChloroquineThe antiacid decreases the absorption of chloroquine
CiprofloxacinFormation of non-absorbable complexes
ClodronateFormation of non-absorbable complexes
DapsoneFormation of non-absorbable complexes
DeferiproneDeferiprone serum concentrations may be decreased by magnesium salts.
DelavirdineMagnesium antacids may decrease the absorption of delavirdine.
DemeclocyclineFormation of non-absorbable complexes
Dihydroquinidine barbiturateThe antiacid decreases the absorption of quinidine
DoxycyclineFormation of non-absorbable complexes
EnoxacinFormation of non-absorbable complexes
Etidronic acidFormation of non-absorbable complexes
FosamprenavirThe antiacid decreases the absorption of amprenavir
GatifloxacinFormation of non-absorbable complexes
GemifloxacinFormation of non-absorbable complexes
GrepafloxacinMagnesium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours.
IbandronateFormation of non-absorbable complexes
IndinavirMagnesium may decrease the absorption of indinavir.
LevofloxacinFormation of non-absorbable complexes
LomefloxacinFormation of non-absorbable complexes
MethacyclineFormation of non-absorbable complexes
MinocyclineFormation of non-absorbable complexes
MoxifloxacinFormation of non-absorbable complexes
NorfloxacinFormation of non-absorbable complexes
OfloxacinFormation of non-absorbable complexes
OxytetracyclineFormation of non-absorbable complexes
PefloxacinFormation of non-absorbable complexes
Polystyrene sulfonateRisk of alkalosis in renal impairment
QuinidineMagnesium antacids may decrease the absorption of quindine.
Quinidine barbiturateThe antiacid decreases the absorption of quinidine
RisedronateFormation of non-absorbable complexes
RosuvastatinMagnesium-containing antacids may decrease the absorption of rosuvastatin.
TemafloxacinFormation of non-absorbable complexes
TetracyclineFormation of non-absorbable complexes
TrovafloxacinFormation of non-absorbable complexes
Food InteractionsNot Available


1. Sodium/potassium-transporting ATPase subunit alpha-1

Kind: protein

Organism: Human

Pharmacological action: unknown


Name UniProt ID Details
Sodium/potassium-transporting ATPase subunit alpha-1 P05023 Details


  1. Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields] Biofizika. 2006 May-Jun;51(3):545-52. Pubmed
  2. Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. Pubmed
  3. Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. Pubmed
  4. Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. Pubmed

comments powered by Disqus
Drug created on July 06, 2007 14:30 / Updated on March 14, 2014 14:52